In a retrospective analysis including 853 patients receiving anti-PD-1/PD-L1, the incidence of bullous skin toxicity was approximately 1%, with bullous pemphigoid (BP) appearing to be the most common presentation, followed by bullous lichenoid dermatitis and linear IgA bullous dermatosis [47]. This evidence concerns the gene CD274 and bullous pemphigoid.